Edition:
United States

Madrigal Pharmaceuticals Inc (MDGL.OQ)

MDGL.OQ on NASDAQ Stock Exchange Capital Market

120.50USD
19 Nov 2018
Change (% chg)

-- (--)
Prev Close
$120.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
86,621
52-wk High
$325.58
52-wk Low
$40.28

Latest Key Developments (Source: Significant Developments)

Madrigal Pharmaceuticals Reports Qtrly Loss Per Share $0.45
Tuesday, 7 Aug 2018 06:50am EDT 

Aug 7 (Reuters) - Madrigal Pharmaceuticals Inc ::MADRIGAL PHARMACEUTICALS REPORTS 2018 SECOND QUARTER FINANCIAL RESULTS AND REVIEWS KEY CLINICAL ACHIEVEMENTS.AS OF JUNE 30, 2018, MADRIGAL HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $490.3 MILLION.QTRLY LOSS PER SHARE $0.45.QTRLY LOSS PER SHARE $0.45.AS OF JUNE 30, 2018, CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $490.3 MILLION, VERSUS $191.5 MILLION AT DEC 31, 2017.Q2 EARNINGS PER SHARE VIEW $-0.63 -- THOMSON REUTERS I/B/E/S.MADRIGAL PHARMACEUTICALS - "WE ARE IN A STRONG POSITION TO EXPEDITE THE MGL-3196 DEVELOPMENT PROGRAM IN NASH AND DYSLIPIDEMIAS".  Full Article

Madrigal'S Mgl-3196 Achieves Liver Biopsy Endpoints In Phase 2 Clinical Trial
Thursday, 31 May 2018 06:50am EDT 

May 31 (Reuters) - Madrigal Pharmaceuticals Inc ::MADRIGAL'S MGL-3196 ACHIEVES LIVER BIOPSY ENDPOINTS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AT 36 WEEKS IN PHASE 2 CLINICAL TRIAL.MADRIGAL PHARMACEUTICALS INC - MGL-3196 WAS WELL-TOLERATED WITH MOSTLY MILD AND A FEW MODERATE AES.MADRIGAL PHARMACEUTICALS INC - IN PHASE 2 CLINICAL TRIAL, MGL-3196 DEMONSTRATED STATISTICAL SIGNIFICANCE IN PRIMARY ENDPOINT.MADRIGAL PHARMACEUTICALS INC - MGL-3196 HAD 7 SAES, NONE DRUG RELATED, NONE OCCURRING MORE THAN ONCE, 5 IN MGL-3196, 2 IN PLACEBO-TREATED PATIENTS.MADRIGAL PHARMACEUTICALS -PHASE 2 CLINICAL TRIAL OF MGL-3196 ALSO SHOWED STATISTICALLY SIGNIFICANT RESULTS IN KEY SECONDARY ENDPOINTS.  Full Article

Madrigal Pharmaceuticals Prices Public Offering Of Common Stock
Monday, 18 Dec 2017 11:26pm EST 

Dec 18 (Reuters) - Madrigal Pharmaceuticals Inc ::MADRIGAL PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK.MADRIGAL PHARMACEUTICALS INC SAYS PRICES OFFERING OF 1.5 MILLION SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $83.00 PER SHARE.  Full Article

Madrigal Pharma Announces Proposed Public Offering Of Common Stock
Monday, 18 Dec 2017 06:50am EST 

Dec 18 (Reuters) - Madrigal Pharmaceuticals Inc ::MADRIGAL PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.MADRIGAL PHARMACEUTICALS INC - ‍COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $100 MILLION OF ITS COMMON STOCK​.  Full Article

Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Biopsy-Proven Non-Alcoholic Steatohepatitis In Phase 2 Clinical Trial
Wednesday, 6 Dec 2017 06:55am EST 

Dec 6 (Reuters) - Madrigal Pharmaceuticals Inc ::MADRIGAL'S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN PHASE 2 CLINICAL TRIAL.MADRIGAL PHARMACEUTICALS INC - MGL-3196 HAS BEEN WELL-TOLERATED WITH MOSTLY MILD AES, AND A FEW MODERATE AES IN STUDY.MADRIGAL PHARMACEUTICALS INC - THERE HAVE BEEN THREE SERIOUS ADVERSE EFFECTS IN STUDY, ALL CONSIDERED UNRELATED TO MGL-3196.MADRIGAL PHARMACEUTICALS - IN TRIAL, MGL-3196 DEMONSTRATED STATISTICALLY SIGNIFICANT RESULTS FOR THE PRIMARY ENDPOINT.  Full Article

Madrigal Pharmaceuticals reports Q3 loss per share of $0.68
Thursday, 9 Nov 2017 07:50am EST 

Nov 9 (Reuters) - Madrigal Pharmaceuticals Inc :Madrigal Pharmaceuticals reports 2017 third quarter financial results.Qtrly loss per share $0.68 ‍​.‍As of Sept 30, had cash, cash equivalents and marketable securities of $62.1 million, versus $40.5 million at December 31, 2016​.On track to report top-line results for nash late this year and hefh early in 2018​.  Full Article

Viking shares surge after fatty liver drug trial

Viking Therapeutics Inc's shares more than doubled in value on Tuesday after promising data from a mid-stage trial of its fatty liver drug were seen as topping that from larger rival Madrigal Pharmaceuticals .